<DOC>
	<DOCNO>NCT00107120</DOCNO>
	<brief_summary>Depression affect approximately 2.5 % child 8 % adolescent . Escitalopram S-enantiomer citalopram . Both escitalopram citalopram selective serotonin reuptake inhibitor ( SSRIs ) use treat depression adult . This study design provide systematic evaluation safety efficacy escitalopram treatment depress pediatric patient , 12 17 year age . Patients complete study eligible enter open-label extension study .</brief_summary>
	<brief_title>The Safety Efficacy Escitalopram Pediatric Patients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Patient must meet Diagnostic Statistical Manual , Fourth Edition ( DSMIV ) diagnostic criterion Major Depressive Disorder . Patient 's current depressive episode must least 12 week duration Patient must parent caregiver must agree accompany patient clinic visit . Patients currently meet DSMIV criterion : 1. attention deficithyperactivity disorder 2. obsessivecompulsive disorder 3. posttraumatic stress disorder 4. bipolar disorder 5. pervasive developmental disorder 6. mental retardation 7. conduct disorder 8. oppositional defiant disorder Patients consider suicide risk ( active suicidal ideation ) , make suicide attempt , ever hospitalize suicide attempt .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Depression</keyword>
	<keyword>Adolescents</keyword>
	<keyword>Escitalopram</keyword>
	<keyword>Pediatrics</keyword>
</DOC>